Fundamentals of Liver Disease- Hepatitis C

5 (10 votes)

There is currently an anticipated shortage of trained providers capable of diagnosing and treating different liver diseases. As a result of this increased demand and limited specialists in the field, more and more front line providers are faced with these patients and do not have the experience or resources that will allow them to manage them appropriately.

The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

Key topic areas:
HCV: Epidemiology and Screening
Patient with new diagnosis of HCV (anti-HCV positive)
Assessing severity of liver disease in HCV
Management of the Patient with Chronic HCV
Management of the Chronic HCV Patient with co-morbid and other conditions
Antiviral treatment of the patient with HCV infection
Management of patients with HCV who have achieved a virological "cure"
The Pediatric patient with HCV

COMPONENTS
Online:
8 online interactive, narrated modules 30 to 40 minutes in length
Pre- and post-test questions for each module

Original release date: April 10, 2014
Review date:July 1, 2017
Re-release date: December 1, 2017
Expiration date: November 30, 2019
Time to complete each module: 45-60 minutes

Copyright:
All faculty in this activity have given their permission for publication OR
©2017 AASLD

Contact Information
For questions on CE credit for this activity contact Certificate@AmedcoEmail.com
For questions on MOC/CME/CE content or the activity web site, contact education@aasld.org.

John W. Ward

Nancy S. Reau

Dr. Nancy Reau is currently Associate Director of Solid Organ Transplantation and Section Chief of Hepatology at Rush University Medical Center. Dr Reau’s research interest is in viral hepatitis drug development as well as utilisation. She has authored or co-authored over 100 peer-reviewed articles, invited reviews, editorials and online programmes, as well as several book chapters, and two books. She is the editor in chief for Clinical Liver Disease, the AASLD multimedia journal.  She was one of the original authors of the AASLD/IDSA hepatitis C guidance document.  She is currently a member of the steering committee for the hepatitis C special interest group for the AASLD and is a member of the gastroenterology writing committee for the American Board of Internal Medicine.

 

Jordan J. Feld

Sanjeev Arora

Raymond T. Chung

Michael W. Fried

Andrew J. Muir

Dr. Andrew Muir is a gastroenterologist whose research activities are focused on developing innovative treatments for a variety of liver diseases. Through his work at the Durham Veterans Administration Medical Center, Dr. Muir has participated in the development programs of many of the direct acting antiviral agents that have revolutionized hepatitis C care. He assumed the leadership of the Gastroenterology and Hepatology Research program at DCRI in 2010 and has expanded the research portfolio to include other liver disorders and gastroenterology outcomes. His particular interests include viral hepatitis, primary sclerosing cholangitis, and liver transplantation. He also has a longstanding interest in healthcare disparities.

Kathleen B. Schwarz

Key:

Complete
Failed
Available
Locked
Module 1: Hepatitis C Epidemiology and Prevention Globally and for the United States
Module 1 Pre-Test
5 Questions  |  1 attempt  |  3/5 points to pass
5 Questions  |  1 attempt  |  3/5 points to pass
Module 1: Hepatitis C Epidemiology and Prevention Globally and for the United States
Open to view video.
Open to view video.
Module 1 Post-Test
5 Questions  |  Unlimited attempts  |  3/5 points to pass
5 Questions  |  Unlimited attempts  |  3/5 points to pass
Module 1 CE Credits
0.50 CE Credits credits  |  Certificate available
0.50 CE Credits credits  |  Certificate available
Module 1 CME Credits
Up to 0.50 medical credits available  |  Certificate available
Up to 0.50 medical credits available  |  Certificate available
Acknowledgement of MOC Submission
Please review and agree to the terms to continue.
Please review and agree to the terms to continue.
Module 1 MOC Points
Up to 0.50 medical credits available  |  Certificate available
Up to 0.50 medical credits available  |  Certificate available
Module 1 Evaluation
4 Questions
4 Questions Please complete the following evaluation form to share your feedback on this activity.
Module 2: My Patient has Tested Positive for Hepatitis C
Module 2 Pre-Test
5 Questions  |  1 attempt  |  3/5 points to pass
5 Questions  |  1 attempt  |  3/5 points to pass
Module 2: My Patient has Tested Positive for Hepatitis C
Open to view video.
Open to view video.
Module 2 Post-Test
5 Questions  |  Unlimited attempts  |  3/5 points to pass
5 Questions  |  Unlimited attempts  |  3/5 points to pass
Module 2 CE Credits
0.50 CE Credits credits  |  Certificate available
0.50 CE Credits credits  |  Certificate available
Module 2 CME Credits
Up to 0.50 medical credits available  |  Certificate available
Up to 0.50 medical credits available  |  Certificate available
Acknowledgement of MOC Submission
Please review and agree to the terms to continue.
Please review and agree to the terms to continue.
Module 2 MOC Points
Up to 0.50 medical credits available  |  Certificate available
Up to 0.50 medical credits available  |  Certificate available
Module 2 Evaluation
4 Questions
4 Questions Please complete the following evaluation form to share your feedback on this activity.
Module 3: Assessing severity of liver disease in HCV
Module 3 Pre-Test
5 Questions  |  1 attempt  |  3/5 points to pass
5 Questions  |  1 attempt  |  3/5 points to pass
Module 3: Assessing severity of liver disease in HCV
Open to view video.
Open to view video.
Module 3 Post-Test
5 Questions  |  Unlimited attempts  |  3/5 points to pass
5 Questions  |  Unlimited attempts  |  3/5 points to pass
Module 3 CE Credits
0.50 CE Credits credits  |  Certificate available
0.50 CE Credits credits  |  Certificate available
Module 3 CME Credits
Up to 0.50 medical credits available  |  Certificate available
Up to 0.50 medical credits available  |  Certificate available
Acknowledgement of MOC Submission
Please review and agree to the terms to continue.
Please review and agree to the terms to continue.
Module 3 MOC Points
Up to 0.50 medical credits available  |  Certificate available
Up to 0.50 medical credits available  |  Certificate available
Module 3 Evaluation
4 Questions
4 Questions Please complete the following evaluation form to share your feedback on this activity.
Module 4: Management of the Patient with Chronic HCV
Module 4 Pre-Test
5 Questions  |  1 attempt  |  3/5 points to pass
5 Questions  |  1 attempt  |  3/5 points to pass
Module 4: Management of the Patient with Chronic HCV
Open to view video.
Open to view video.
Module 4 Post-Test
5 Questions  |  Unlimited attempts  |  3/5 points to pass
5 Questions  |  Unlimited attempts  |  3/5 points to pass
Module 4 CE Credits
0.50 CE Credits credits  |  Certificate available
0.50 CE Credits credits  |  Certificate available
Module 4 CME Credits
Up to 0.50 medical credits available  |  Certificate available
Up to 0.50 medical credits available  |  Certificate available
Acknowledgement of MOC Submission
Please review and agree to the terms to continue.
Please review and agree to the terms to continue.
Module 4 MOC Points
Up to 0.50 medical credits available  |  Certificate available
Up to 0.50 medical credits available  |  Certificate available
Module 4 Evaluation
4 Questions
4 Questions Please complete the following evaluation form to share your feedback on this activity.
Module 5: Management of the Chronic HCV Patient with Comorbid and Other Conditions
Module 5 Pre-Test
4 Questions  |  1 attempt  |  3/4 points to pass
4 Questions  |  1 attempt  |  3/4 points to pass
Module 5:Management of the Chronic HCV Patient with Comorbid and Other Conditions
Open to view video.
Open to view video.
Module 5 Post-Test
4 Questions  |  Unlimited attempts  |  3/4 points to pass
4 Questions  |  Unlimited attempts  |  3/4 points to pass
Module 5 CE Credits
0.50 CE Credits credits  |  Certificate available
0.50 CE Credits credits  |  Certificate available
Module 5 CME Credits
Up to 0.50 medical credits available  |  Certificate available
Up to 0.50 medical credits available  |  Certificate available
Acknowledgement of MOC Submission
Please review and agree to the terms to continue.
Please review and agree to the terms to continue.
Module 5 MOC Points
Up to 0.50 medical credits available  |  Certificate available
Up to 0.50 medical credits available  |  Certificate available
Module 5 Evaluation
4 Questions
4 Questions Please complete the following evaluation form to share your feedback on this activity.
Module 6: Antiviral treatment of the patient with HCV infection
Module 6 Pre-Test
5 Questions  |  1 attempt  |  3/5 points to pass
5 Questions  |  1 attempt  |  3/5 points to pass
Module 6: Antiviral treatment of the patient with HCV infection
Open to view video.
Open to view video.
Module 6 Post-Test
5 Questions  |  Unlimited attempts  |  3/5 points to pass
5 Questions  |  Unlimited attempts  |  3/5 points to pass
Module 6 CE Credits
0.50 CE Credits credits  |  Certificate available
0.50 CE Credits credits  |  Certificate available
Module 6 CME Credits
Up to 0.50 medical credits available  |  Certificate available
Up to 0.50 medical credits available  |  Certificate available
Acknowledgement of MOC Submission
Please review and agree to the terms to continue.
Please review and agree to the terms to continue.
Module 6 MOC Points
Up to 0.50 medical credits available  |  Certificate available
Up to 0.50 medical credits available  |  Certificate available
Module 6 Evaluation
4 Questions
4 Questions Please complete the following evaluation form to share your feedback on this activity.
Module 7: Management of Patients with HCV who Have Achieved a Virological
Module 7 Pre-Test
4 Questions  |  1 attempt  |  3/4 points to pass
4 Questions  |  1 attempt  |  3/4 points to pass
Module 7: Management of Patients with HCV who Have Achieved a Virological
Open to view video.
Open to view video.
Module 7 Post-Test
4 Questions  |  Unlimited attempts  |  3/4 points to pass
4 Questions  |  Unlimited attempts  |  3/4 points to pass
Module 7 CE Credits
0.50 CE Credits credits  |  Certificate available
0.50 CE Credits credits  |  Certificate available
Module 7 CME Credits
Up to 0.50 medical credits available  |  Certificate available
Up to 0.50 medical credits available  |  Certificate available
Acknowledgement of MOC Submission
Please review and agree to the terms to continue.
Please review and agree to the terms to continue.
Module 7 MOC Points
Up to 0.50 medical credits available  |  Certificate available
Up to 0.50 medical credits available  |  Certificate available
Module 7 Evaluation
4 Questions
4 Questions Please complete the following evaluation form to share your feedback on this activity.
Module 8: The Pediatric patient with HCV
Module 8 Pre-Test
5 Questions  |  1 attempt  |  3/5 points to pass
5 Questions  |  1 attempt  |  3/5 points to pass
Module 8: The Pediatric patient with HCV
Open to view video.
Open to view video.
Module 8 Post-Test
5 Questions  |  Unlimited attempts  |  3/5 points to pass
5 Questions  |  Unlimited attempts  |  3/5 points to pass
Module 8 CE Credits
0.50 CE Credits credits  |  Certificate available
0.50 CE Credits credits  |  Certificate available
Module 8 CME Credits
Up to 0.50 medical credits available  |  Certificate available
Up to 0.50 medical credits available  |  Certificate available
Acknowledgement of MOC Submission
Please review and agree to the terms to continue.
Please review and agree to the terms to continue.
Module 8 MOC Points
Up to 0.50 medical credits available  |  Certificate available
Up to 0.50 medical credits available  |  Certificate available
Module 8 Evaluation
4 Questions
4 Questions Please complete the following evaluation form to share your feedback on this activity.
Final Evaluation
Final Evaluation
4 Questions
4 Questions Please complete the following evaluation form to share your feedback on this activity.

Learning Objective:

• Identify patients with liver disease
• Apply diagnostic tests appropriately
• Discuss important counseling
• Recognize treatment/referral priorities
• Identify first line therapies for different liver diseases
• Refer to specialist in a timely and appropriate fashion

This curriculum was developed for Primary Care Providers and any other healthcare provider interested in liver disease.

CME

Accreditation Statement

The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

AASLD designates this enduring activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse

Amedco is accredited as a provider of continuin nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This course is co-provided by Amedco and AASLD. Maximum of 4.0 contact hours.

Maintenance of Certification (MOC) Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

How to Earn/Claim MOC

 

•    For each module that you wish to claim MOC points for you must:

 

            o    Complete the pre-test

 

            o    Review/watch the slides in the presentation

 

            o    Complete the post-test and pass with a score of 70% or higher (Participants have unlimited attempts to earn the passing score.)

 

            o    Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)

 

•    AASLD submits MOC points on behalf of its learners to ABIM once a month between 15th-20th. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.

 

•    MOC points are available for ABIM board certified physicians only.

DISCLOSURE OF CONFLICTS OF INTEREST

AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing health-care related products and/or services. Disclosures are collected prior to the start of the educational activity any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.
The faculty, organizers and reviewers have reported the following disclosures:

Juan Abraldes, MD
Faculty
Nothing to disclose

Jasmahon Bajaj, MD
Faculty
Advisory Committees or Review Panels: ALF, ACG
Consulting: Salix, Norgine and Alfa-Wasserman 
Grant/Research Support: Grifols, Salix

Thomas Boyer, MD
Faculty
Consulting: Ikaria
Grant/Research Support: Ikaria

Michael Fallon, MD
Faculty
Nothing to disclose

Patrick Kamath, MD
Faculty
Advisory Committees or Review Panels: Sequana

Paul Martin, MD
Faculty
Grant/Research Support: AbbVie and Genfit

Puneeta Tandon, MD
Faculty
Nothing to disclose

Florence Wong, MD
Faculty
Speakers' Bureau: L.W. Gore & Associates

Sanjeev Arora, MD
Organizer
Advisory Committee: CDC Advisory Committee - Hep C
Grant/Research Support: Gilead, Beckman Coulter, Merck, AbbVie

Lauren Beste, MD
Organizer
Nothing to disclose

Michael Fried, MD, FAASLD
Organizer
Grant/Research Support: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck and NIH
Scientific Consultant: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck and TARGET PharmaSolutions

Guadalupe Garcia-Tsao, MD
Organizer, Faculty
Advisory Committee: Abbvie, Fibrogen

Leslie Hayes, MD
Organizer
Nothing to disclose

Patrick Horne, MSN, ARNP, FNP-BC
Organizer
Consulting: Gilead Sciences, Bristol-Myers-Squibb, AbbVie

Rennie Mills, PA-C
Organizer
Advisory Board: Gilead

Minhhuyen Nguyen, MD
Organizer
Nothing to disclose

Norah Terrault, MD
Organizer
Consulting: Dynavax Technologies, Novartis Pharmaceuticals, Echosens North America Inc
Continuing Medical Education: Practice Point Communications, Focus Medical Communications, Med IQ, PRIME Education Inc 
Educational Material Development: CCO Hepatitis

John Ward, MD
Organizer
Nothing to disclose

Stephanie Graham, MA
AASLD Staff
Nothing to disclose

Claudia Ventura
AASLD Staff
Nothing to disclose

Online Learning Committee

Calvin Q. Pan, MD, MACP, FAASLD
Reviewer
Advisory Board: BMS, Gilead, Abbvie Grants/Research Support:  Gilead, Merck  Speakers Bureau: BMS, Gilead, Abbvie, salix, Synergy

Lopa Mishra, MD, FAASLD
Reviewer
Nothing to Disclose

Gene Y Im, MD
Reviewer
Nothing to Disclose

Iris W Liou, MD
Reviewer
Nothing to Disclose

Jesse M Civan, MD
Reviewer
Education: Merck

HoChong Gilles, FNP
Reviewer
Nothing to Disclose

Julius Wilder, MD, PhD
Reviewer
Nothing to Disclose

Nicolas M Intagliata, MD
Reviewer
Consulting: Vital Therapies Grants/Research Support: Vital Therapies, Eisai, Sequana Medical

Andrew S. deLemos, MD
Reviewer
Consulting: Novartis

Samar H. Ibrahim, MBCHB
Reviewer
Nothing to Disclose

This enduring material may contain discussion of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference of an unlabeled or investigational use.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Acknowledgement of Commercial Support:
No commercial support was received for this enduring material activity.